Teva is the leading generics company in America, with $20.3 billion in net revenues in 2012. Teva Americas is headquartered in North Wales, Pennsylvania, and has over 13,000 employees in 13 US states, the District of Columbia, Canada, Puerto Rico, Argentina, Brazil, Chile, Mexico, Peru, Uruguay and Venezuela. Over 1.5 million Teva prescriptions are written each day in the US alone, or 1,073 prescriptions per minute, while 1 out of every 6 generic prescriptions in the US and Canada is filled with a Teva product.
Teva Japan is one of the top three generic pharmaceutical companies in Japan, employing approximately 2,000 people. Headquartered in Tokyo and Nagoya, Teva Japan markets specialty products (in collaboration with local companies), generic medicines and APIs. In South Korea, Teva has established a business venture, Teva-Handok. Teva-Handok is now planning to introduce a strong pipeline based on Teva generics and specialty products in order to bring high-quality and affordable medicines to patients in South Korea. Commercial operations are expected to start in September 2013.
Teva EMIA-APAC coordinates Teva’s commercial activities in Eastern Europe (Russia, Ukraine, Kazakhstan and all other CIS countries), the Middle East, Israel, Africa and Asia-Pacific, including, among others, China and India. Teva EMIA-APAC has rapidly developed a robust organization that provides strong added value. Teva is already a leader in key regional markets, and is continually working to increase its presence in the rest of the territories.
With its headquarters in The Netherlands, Teva Europe is employing approximately 15,000 people in the region. Teva Europe markets a range of specialty medicines, generic medicines, active pharmaceutical ingredients (API) and OTC products.
Covering 36 countries, including the 27 European Union member states, we’re Europe’s biggest provider of tried-and-trusted generic medicines we estimate that, on average, every single second of every single day, 2,500 Teva packs are dispensed in the EU. We estimate that it saves around €8 billion every year from Europe’s healthcare budget by supplying cost-effective treatments.